Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-finding study of asundexian (BAY 2433334) after acute non-cardioembolic ischemic stroke
jRCT2080225214Phase 2Completed
- Sponsor
- Bayer
- Start
- Jun 2020
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in Noncardioembolic stroke (NCES) comparing Asundexian arm with Placebo arm (2 arms). Started Jun 2020; status: completed.
02
Drugs
asundexian
03
Conditions
Noncardioembolic stroke (NCES)
Beyond the preview
Go deeper on jRCT2080225214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225214.